EUVIMED · CrossrefZeitschrift
AME Clinical Trials Review
ISSN 3005-6152 · AME Publishing Company
Neueste Artikel
Targeting the TGF-β pathway in patients with non-small cell lung cancer
Towards better outcomes: segmentectomy for ground-glass opacity-dominant non-small cell lung cancer 3 cm or less—insights from JCOG1211
Changing the way we treat KRAS G12C non-small cell lung cancers
Pafolacianine for imaging of pulmonary neoplasms: a promising supplement for modern surgical technique
Segmentectomy for partially solid non-small cell lung cancer: what counts—the resection or the patient?
The importance of long-term safety, tolerability, and health-related quality of life: lessons from the ADAURA trial
Real world data are needed to establish safety of adjuvant immune checkpoint inhibitors after pneumonectomy
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
Two-year analysis of CodeBreaK 100 phase I/II trial: achieved goals of an ongoing challenge
Overall survival of ADAURA: game, set, and match?
Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review
The ELUCIDATE trial: a step closer to complete resection of lung tumors
Editorial commentary: the importance of staging hasn’t changed, but the procedure of choice has
Combining neoadjuvant and adjuvant immunotherapy breathes more life into the growing body of lung cancer treatment paradigms
Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer
What is the most optimal postoperative chest tube placement method after lung resection?
NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?
Chest tube after lung resection—a small change to a great benefit
New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients
Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial
EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges
Tunnel vision: seeking to reduce peritubular leakage after lung resection
Real-world evidence for immune checkpoint inhibitors in extensive-stage small cell lung cancer
The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC
Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC)
How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer
Commentary: is segmentectomy curative in patients with early-stage ground glass opacity predominant non-small cell lung cancer?
An ever-stronger case for circulating tumor DNA monitoring in ALK+ lung cancer
EUVIMED